Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research Post published:April 12, 2022 Post category:Press Release
Novamind Partners with Merck for New Treatment-Resistant Depression Trial Post published:March 18, 2021 Post category:Press Release
Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter Post published:March 1, 2021 Post category:Press Release
Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF Post published:February 22, 2021 Post category:Press Release
Novamind Announces Marketing Services Agreements Post published:January 26, 2021 Post category:Press Release
Novamind Expands Psychedelic Medicine Access in Utah Post published:January 13, 2021 Post category:Press Release
Novamind Completes Reverse Takeover Transaction Post published:December 24, 2020 Post category:Press Release
Novamind Receives CSE Conditional Listing Approval Under the Ticker “NM” Post published:December 22, 2020 Post category:Press Release
Novamind Closes Oversubscribed CAD$10 Million Private Placement Post published:November 23, 2020 Post category:Press Release
Novamind and Hinterland Metals Enter into Amalgamation Agreement Post published:November 17, 2020 Post category:Press Release